EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Irreversible Electroporation Combined With Dendritic Cell-based Vaccines for the Treatment of Osteosarcoma

Chong Sun, Xuexiao Ma, Chuanli Zhou, Zhuoli Zhang, Jianwei Guo

Anticancer Research · 2023

DOI: 10.21873/anticanres.16514 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Anticancer Research, 2023. Verfasst von Chong Sun und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Spinal Surgery, The Affiliated Hospital of Qingdao University, Qingdao, P.R. China. Hauptthemen laut MEDLINE: Cancer Vaccines, Osteosarcoma, Bone Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Osteosarcoma is the most common primary bone malignancy, and surgical resection combined with neoadjuvant chemotherapy is the gold-standard treatment for affected patients. Although the overall survival rates for patients with osteosarcoma currently range from 60% to 70%, outcomes remain disappointing for patients with recurrent, metastatic, or unresectable disease. Irreversible electroporation (IRE) is a novel ablation technique with the potential to elicit an immune response in solid tumors. Dendritic cell (DC)-based tumor vaccines have shown promising therapeutic efficacy in preclinical studies focused on osteosarcoma; however, only limited therapeutic efficacy has been observed in clinical trials. Thus, there is considerable potential therapeutic value in developing combination osteosarcoma treatments that involve IRE and DC-based tumor vaccines. In this review, we discuss recent advances in preclinical and clinical DC-based immunotherapies, as well as potential combinations of DC-based vaccines and IRE, that may improve therapeutic outcomes for patients with osteosarcoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cancer VaccinesOsteosarcomaBone NeoplasmsHumansElectroporationDendritic CellsTreatment Outcome

Stichwörter der Autor:innen

Dendritic cellscombination therapiesirreversible electroporationosteosarcomareviewvaccine

Substanzen

Cancer Vaccines

Autor:innen und Institutionen

  • Department of Spinal Surgery, The Affiliated Hospital of Qingdao University, Qingdao, P.R. China.
  • Department of Radiological Sciences, University of California Irvine, Irvine, CA, U.S.A.; zhuoliz1@hs.uci.edu.
  • Chao Family Comprehensive Cancer Center, University of California Irvine, Irvine, CA, U.S.A.
  • Department of Biomedical Engineering, University of California Irvine, Irvine, CA, U.S.A.
  • Department of Pathology and Laboratory Medicine, University of California Irvine, Irvine, CA, U.S.A.
  • Department of Spinal Surgery, The Affiliated Hospital of Qingdao University, Qingdao, P.R. China; guojw_qdfy@163.com.

Förderung

  • NCI NIH HHS

Zitieren

APA

Sun, C., Ma, X., Zhou, C., Zhang, Z., & Guo, J. (2023). Irreversible Electroporation Combined With Dendritic Cell-based Vaccines for the Treatment of Osteosarcoma. Anticancer Research. https://doi.org/10.21873/anticanres.16514

Vancouver

Sun C, Ma X, Zhou C, Zhang Z, Guo J. Irreversible Electroporation Combined With Dendritic Cell-based Vaccines for the Treatment of Osteosarcoma. Anticancer Research. 2023. doi:10.21873/anticanres.16514

BibTeX
@article{Sun2023,
  author = {Sun, Chong and Ma, Xuexiao and Zhou, Chuanli and Zhang, Zhuoli and Guo, Jianwei},
  title = {Irreversible Electroporation Combined With Dendritic Cell-based Vaccines for the Treatment of Osteosarcoma},
  journal = {Anticancer Research},
  year = {2023},
  doi = {10.21873/anticanres.16514}
}
Kostenlos starten →